- Home
- CRL vs ELAN Comparison
CRL vs ELAN Comparison
Compare CRL & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRL | ELAN |
|---|---|---|
| Founded | 1947 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 12.4B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CRL | ELAN |
|---|---|---|
| Price | $288.50 | $24.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $198.27 | $27.89 |
| AVG Volume (30 Days) | 848.5K | ★ 6.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | $1,857,601,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | N/A | $8.21 |
| Revenue Next Year | $3.04 | $5.31 |
| P/E Ratio | ★ N/A | $110.09 |
| Revenue Growth | ★ 10.48 | 6.22 |
| 52 Week Low | $144.26 | $18.22 |
| 52 Week High | $303.31 | $27.98 |
Technical Indicators
Market Signals| Indicator | CRL | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 49.54 |
| Support Level | $215.89 | $23.40 |
| Resistance Level | $303.31 | $25.77 |
| Average True Range (ATR) | 9.54 | 0.70 |
| MACD | -2.67 | 0.06 |
| Stochastic Oscillator | 43.54 | 49.03 |
Price Performance
Historical ComparisonAbout CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.